タシラゴンはMRGPRX2媒介のマスト細胞の脱粒化を阻害し,偽アレルギー反応を抑制する
Pingping Yan1, Tingting Huang2, Mawusse K I Attiogbe2
1Department of Pharmacology, School of Basic Medical Sciences, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi 710061, China; Department of Pharmacy, Xi'an Children's Hospital, Xi'an Jiaotong University, Xi'an 710003, China.
Toxicology and applied pharmacology
|February 18, 2026
まとめ
タシラゴン (Tus) は,マスト細胞の活性化と下流の信号伝達経路を抑制することによって,偽アレルギー反応を効果的に抑制します. この天然化合物は,偽アレルギーのような状態の治療に治療的可能性を示しています.
科学分野:
- 薬理学 薬理学とは
- 免疫学 免疫学とは
- 自然製品 自然製品
背景:
- マス関連Gタンパク質結合受容体X2 (MRGPRX2) は,偽アレルギー反応に関与しています.
- Tussilago farfaraのTussilagone (Tus) は,抗炎症的性質を持っているが,偽アレルギーにおけるその役割は不明である.
研究 の 目的:
- 偽アレルギー反応に対するタシラゴン (Tus) の抑制効果を調査する.
- Tusの作用の基礎となる分子メカニズムを解明する.
主な方法:
- 系統的擬似アレルギーおよび受動性皮膚アナフィラキシー (PCA) モデルを用いたインビボ試験.
- マスト細胞のデグラヌレーション,サイトカインの放出 (TNF-α,IL-8,MCP-1),およびシグナル伝達経路 (Lyn/Btk,p38 MAPK,NF-κB) のインビトロ分析.
- MRGPRX2発現細胞におけるカルシウム (Ca2+) 流入の評価.
主要な成果:
- Tusは,真偽アレルギー反応とPCAを in vivo で著しく減少させました.
- Tusは,マスト細胞のデグラヌレーションと炎症性サイトカインの産生を抑制しました.
- Tusは,Lyn,Btk,PLCγ1,p38 MAPK,NF-κBを含むCa2+の流入と下流のシグナリング分子を阻害しました.
結論:
- タシラゴンは,MRGPRX2媒介のマスト細胞活性化をターゲットにすることで,偽アレルギー反応を弱める.
- Tusは重要なシグナル伝達経路 (Lyn/Btk/PLCγ1およびp38/NF-κB) を調節し,偽アレルギーの治療の可能性を示しています.
キーワード:
リン・リン・リン リン・リンMRGPRX2は,MRGPRX2と一致している.マスト細胞はマスト細胞である.トッシラゴーネ (Tussilagone) とは トッシラゴーネ (Tussilagone) とは偽アレルギーの反応さらに関連する動画
関連する概念動画
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.9K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.9K
Antiasthma Drugs: Leukotriene Modifiers
1.9K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.9K
Allergic Drug Reactions
1.5K
Allergic reactions related to drugs are hypersensitivity responses driven by the immune system and bear no connection to the drug's therapeutic action. While drugs in isolation do not trigger an immune response, they can interact with endogenous proteins to form antigens. These antigens stimulate lymphocytes to produce antibodies. IgE-type antibodies attach themselves to mast cells. Upon subsequent exposure to the same stimulus, the antigen-antibody interaction is initiated, unleashing...
1.5K
Antiasthma Drugs: Muscarinic Receptor Antagonists
1.9K
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
1.9K
Allergic Reactions
32.6K
Overview
32.6K
T Cell Types and Functions
2.7K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.7K


